PLRG1

Across TCGA pan-cancer cohorts, PLRG1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLRG1 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLRG1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLRG1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where PLRG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.267	0.433	.034	7	view →
LSCC	DFS	Median	II,III,IV	0.813	0.576	.019	4	view →
LUAD	OS	Median	III,IV	0.808	0.299	.026	4	view →
HNSC	OS	Median	II,III,IV	1.000	0.956	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLRG1–PDAC (DFS)

Open the PDAC breakdown →